Case 3:18-cv-00347-CAB-MDD Document 300-16 Filed 01/08/21 PageID.27096 Page 1 of
`17
`
`EXHIBIT 15
`
`EXHIBIT 15 - Page 169
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-16 Filed 01/08/21 PageID.27097 Page 2 of
`17
`
`
`
`
`WILSON SONSINI GOODRICH & ROSATI, P.C.
`PAUL D. TRIPODI II (SBN 162380)
`ptripodi@wsgr.com
`GRACE J. PAK (SBN 277705)
`gpak@wsgr.com
`633 West Fifth Street, Suite 1550
`Los Angeles, CA 90071
`Telephone: 323-210-2900
`Fax: 866-974-7329
`
`WENDY L. DEVINE (SBN 246337)
`wdevine@wsgr.com
`One Market Plaza
`Spear Tower, Suite 3300
`San Francisco, CA 94105
`Telephone: 415-947-2000
`Fax: 415-947-2099
`
`NATALIE J. MORGAN (SBN 211143)
`nmorgan@wsgr.com
`CHRISTINA DASHE (SBN 292360)
`cdashe@wsgr.com
`12235 El Camino Real
`San Diego, CA 92130
`Telephone: 858-350-2300
`Fax: 858-350-2399
`
`SARA L. TOLBERT (SBN 300945)
`stolbert@wsgr.com
`650 Page Mill Road
`Palo Alto, CA 94304
`Telephone: (650) 593-9300
`Fax: (650) 493-6811
`
`Attorneys for Plaintiff NuVasive, Inc.
`
`UNITED STATES DISTRICT COURT
`
`SOUTHERN DISTRICT OF CALIFORNIA
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`
`
`
`Plaintiff,
`
`
`
`v.
`
`SAN DIEGO DIVISION
`NUVASIVE, INC., a Delaware
`)
`CASE NO. 18-cv-00347-CAB-MDD
`corporation,
`)
`
`
`)
`PLAINTIFF NUVASIVE, INC.’S
`)
`SUPPLEMENTAL RESPONSES
`)
`TO SECOND SET OF
`)
`INTERROGATORIES
`)
`[NOS. 13-15]
`)
`
`)
`Complaint Filed: February 13, 2018
`)
`
`)
`
`)
`
`
`
`ALPHATEC HOLDINGS, INC., a
`Delaware corporation and ALPHATEC
`SPINE, INC., a California corporation,,
`
`
`Defendants.
`NUVASIVE’S SUPPLEMENTAL
`RESPONSES TO 2nd SET OF
`INTERROGATORIES
`
`
` 3:18-cv-00347-CAB-MDD
`
`
`
`
`
`EXHIBIT 15 - Page 170
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-16 Filed 01/08/21 PageID.27098 Page 3 of
`17
`
`
`
`
`Pursuant to Rule 26 and 33 of the Federal Rules of Civil Procedure, Plaintiff
`
`NuVasive, Inc. (“NuVasive”), by and through its undersigned counsel, hereby
`
`provides supplemental responses to Defendants Alphatec Holdings, Inc. and
`
`Alphatec Spine, Inc.’s (collectively “Alphatec” or “Defendants”) Second Set of
`
`Interrogatories (Nos. 13-15) as follows:
`
`GENERAL OBJECTIONS
`
`In addition to any specifically stated objections, NuVasive’s responses
`
`herein are subject to and incorporate the following general objections:
`
`1.
`
`NuVasive asserts each of the following General Objections and
`
`expressly incorporates them into each response set forth below. By providing a
`
`response to any interrogatory, NuVasive does not waive or otherwise limit these
`
`General Objections. Furthermore, reference to any of these General Objections in
`
`any specific response shall not waive or otherwise limit the applicability of all of
`
`these General Objections to each and every response.
`
`2.
`
`NuVasive objects to all definitions, instructions, and interrogatories to
`
`the extent that they are unduly burdensome and oppressive, overly broad, vague,
`
`ambiguous and/or to the extent it is inconsistent with and/or seeks to impose upon
`
`NuVasive obligations beyond those required by the Federal Rules of Civil
`
`Procedure, the Local Rules of the United States District Court for the Southern
`
`District of California or any Court Order in this matter, including this Court’s
`
`Scheduling Order. In responding to these interrogatories, NuVasive will only
`
`comply with the obligations imposed on it by the Federal Rules of Civil Procedure,
`
`the Local Rules of the United States District Court for the Southern District of
`
`California, any applicable orders of this Court, and any stipulation or agreement
`
`between the parties.
`
`NUVASIVE’S SUPPLEMENTAL
`RESPONSES TO 2nd SET OF
`INTERROGATORIES
`
`
`
`- 1 -
`
` 3:18-cv-00347-CAB-MDD
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`
`
`
`EXHIBIT 15 - Page 171
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-16 Filed 01/08/21 PageID.27099 Page 4 of
`17
`
`
`
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`
`
`
`burdensome, and inconsistent with and/or seeks to impose upon NuVasive
`
`obligations beyond those required by the Federal Rules of Civil Procedure.
`
`SUPPLEMENTAL RESPONSES TO INTERROGATORIES
`
`INTERROGATORY NO. 13:
`
`Identify each product that NuVasive contends embodies any asserted claims
`
`of the patents-in-suit and/or competes with any accused product, including, for
`
`NuVasive products, identification of each asserted claim NuVasive contends is
`
`embodied by each such product and the first (1) description in print, (2) offer for
`
`sale, (3) sale, (4) public disclosure, and (5) use of each such product; and for each
`
`non-NuVasive product, identification of NuVasive’s first (1) awareness, (2)
`
`knowledge of any offers for sale, (3) knowledge of any sales, and (4) knowledge
`
`of any use of each such product.
`
`RESPONSE TO INTERROGATORY NO. 13:
`
`NuVasive incorporates by reference each of the General Objections.
`
`NuVasive objects to this interrogatory on the grounds that it contains at least nine
`
`discrete subparts, is compound, and constitutes at least nine interrogatories.
`
`NuVasive objects to this interrogatory as vague and ambiguous with respect to the
`
`terms “competes with,” “identification,” “NuVasive’s first awareness,”
`
`“NuVasive’s first knowledge,” and “any use.” NuVasive objects to this
`
`interrogatory on the grounds and to the extent it is overly broad, unduly
`
`burdensome, not proportional to the needs of the case, and not relevant to any claim
`
`or defense in this case. Specifically, NuVasive objects to this interrogatory to the
`
`extent it seeks information concerning third-party products. Relatedly, with respect
`
`to the “Accused Products,” this interrogatory seeks information that is duplicative
`
`of the information set forth in NuVasive’s Disclosure of Asserted Claims and
`
`Infringement Contentions; to the extent this interrogatory seeks information beyond
`
`such duplicative information, this interrogatory seeks information that is overbroad,
`
`NUVASIVE’S SUPPLEMENTAL
`RESPONSES TO 2nd SET OF
`INTERROGATORIES
`
`
`
`- 10 - 3:18-cv-00347-CAB-MDD
`
`EXHIBIT 15 - Page 172
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-16 Filed 01/08/21 PageID.27100 Page 5 of
`17
`
`
`
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`
`
`
`not relevant to any claim or defense in this case, and is not proportional to the needs
`
`of this case. NuVasive will respond to this interrogatory to the extent it seeks
`
`information regarding NuVasive’s products. For similar reasons, NuVasive objects
`
`to this interrogatory to the extent it seeks information regarding various “first”
`
`activities to the extent such activities cannot constitute prior art to any of the
`
`patents-in-suit. NuVasive also objects to this interrogatory because it is unlimited
`
`as to time. NuVasive objects to this interrogatory to the extent it seeks “Privileged
`
`Information.” NuVasive objects to this interrogatory to the extent it calls for legal
`
`conclusions. NuVasive objects to this interrogatory to the extent it seeks
`
`information that is not and/or is no longer in NuVasive’s possession, custody, or
`
`control. NuVasive objects to this interrogatory to the extent it seeks information
`
`that is publicly available and/or equally available to Alphatec and NuVasive, and is
`
`therefore as easily obtainable by Alphatec as NuVasive. NuVasive objects to this
`
`interrogatory to the extent it seeks information duplicative of the information
`
`sought in Alphatec’s Interrogatory No. 3. NuVasive objects to this interrogatory as
`
`premature to the extent it seeks expert testimony. NuVasive will provide expert
`
`reports with its positions regarding Alphatec’s infringement of the asserted claims
`
`of the patents-in-suit and NuVasive’s products’ embodiment of the asserted claims
`
`of the patents-in-suit at the time set forth in the Court’s scheduling order.
`
`Subject to and without waiving the foregoing objections, NuVasive responds
`
`as follows: NuVasive incorporates by reference its Complaint (Doc. No. 1), its
`
`Memorandum of Points and Authorities in Support of Motion for Preliminary
`
`Injunction (Doc. No. 37-1), the Declaration of Jim A. Youssef, M.D., in Support of
`
`NuVasive’s Motion for Preliminary Injunction (Doc. No. 37-45), NuVasive’s Reply
`
`in Support of its Motion for Preliminary Injunction (Doc. No. 77), the Reply
`
`Declaration of Jim A. Youssef, M.D. in Support of NuVasive’s Motion for
`
`Preliminary Injunction (Doc. No. 77-56), and the Reply Declaration of Matthew
`
`NUVASIVE’S SUPPLEMENTAL
`RESPONSES TO 2nd SET OF
`INTERROGATORIES
`
`
`
`- 11 - 3:18-cv-00347-CAB-MDD
`
`EXHIBIT 15 - Page 173
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-16 Filed 01/08/21 PageID.27101 Page 6 of
`17
`
`
`
`
`Link in Support of NuVasive’s Motion for Preliminary Injunction (Doc. No. 77-
`
`52). In addition, NuVasive states the following based on its knowledge and
`
`information collected to date:
`
`XLIF
`
`NuVasive states that various components and versions of its “eXtreme
`
`Lateral Interbody Fusion” product (or “XLIF”), which includes the MaXcess access
`
`system and CoRoent XL implants, or their use embody the asserted claims of the
`
`patents-in-suit, and further notes that Alphatec has admitted that XLIF embodies
`
`the asserted claims of the patents-in-suit. Doc. No. 48 at 16. NuVasive further
`
`incorporates by reference its Disclosure of Asserted Claims and Infringement
`
`Contentions, which identifies the XLIF components or the use thereof that embody
`
`the asserted claims of the patents-in-suit. NuVasive also incorporates by reference
`
`its response to Alphatec’s Interrogatory No. 3 (and all supplements thereto), which
`
`sets forth the dates various components of XLIF were launched.
`
`In addition, pursuant to Local Patent Rule 3.2(b) and Fed. R. Civ. P. 33(d),
`
`NuVasive states it will produce and has produced non-privileged documents from
`
`which the information requested with respect to XLIF can be ascertained, including
`
`documents bearing the following Bates numbers:
`
`NUVA_ATEC0000544 – NUVA_ATEC0014446;
`
`NUVA_ATEC0015491 – NUVA_ATEC0015614;
`
`NUVA_ATEC0040546 – NUVA_ATEC0040644.
`
`The Accused Products
`
`NuVasive incorporates by reference its Disclosure of Asserted Claims and
`
`Infringement Contentions, which identifies the components of Alphatec’s Battalion
`
`Lateral System with Squadron Lateral Retractor (“the Accused Products”) or the
`
`use thereof that infringe the asserted claims of the patents-in-suit. Additionally,
`
`based on information available to NuVasive at this time, NuVasive states that it is
`
`NUVASIVE’S SUPPLEMENTAL
`RESPONSES TO 2nd SET OF
`INTERROGATORIES
`
`
`
`- 12 - 3:18-cv-00347-CAB-MDD
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`
`
`
`EXHIBIT 15 - Page 174
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-16 Filed 01/08/21 PageID.27102 Page 7 of
`17
`
`
`
`
`aware that the Accused Products were launched on a limited basis in April 2017,
`
`and were fully commercially launched in October 2017.
`
`Discovery is ongoing and NuVasive reserves its right to amend or
`
`supplement its response to this interrogatory.
`
`SUPPLEMENTAL RESPONSE TO INTERROGATORY NO. 13:
`
`In addition to its previously asserted General and Specific Objections,
`
`NuVasive continues to object that this interrogatory is overly broad, unduly
`
`burdensome, and not proportional to the needs of the case because it seeks
`
`identification of information from up to nearly two decades ago that is no longer
`
`readily accessible to NuVasive due to the passage of time and relevant personnel
`
`departing the company over the intervening 15-plus years. Relatedly, NuVasive
`
`also objects that this interrogatory seeks information, including third party products,
`
`not readily or reasonably available to NuVasive. In light of this, NuVasive
`
`maintains that its previous response and citation to documents pursuant to Fed. R.
`
`Civ. P. 33(d) is proper at least because the burden of deriving the requested
`
`information would be substantially the same for either NuVasive or Alphatec.
`
`Subject to and without waiving the foregoing objections, NuVasive further
`
`states: NuVasive’s contentions and facts it intends to rely upon to support its
`
`contentions regarding embodying and competitor products that are contained within
`
`NuVasive’s Complaint (Doc. No. 1), its Memorandum of Points and Authorities in
`
`Support of Motion for Preliminary Injunction (Doc. No. 37-1), the Declaration of
`
`Jim A. Youssef, M.D. in Support of NuVasive’s Motion for Preliminary Injunction
`
`(Doc. No. 37-45), NuVasive’s Reply in Support of its Motion for Preliminary
`
`Injunction (Doc. No. 77), the Reply Declaration of Jim A. Youssef, M.D. in
`
`Support of NuVasive’s Motion for Preliminary Injunction (Doc. No. 77-56), and
`
`the Reply Declaration of Matthew Link in Support of NuVasive’s Motion for
`
`NUVASIVE’S SUPPLEMENTAL
`RESPONSES TO 2nd SET OF
`INTERROGATORIES
`
`
`
`- 13 - 3:18-cv-00347-CAB-MDD
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`
`
`
`EXHIBIT 15 - Page 175
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-16 Filed 01/08/21 PageID.27103 Page 8 of
`17
`
`
`
`
`Preliminary Injunction (Doc. No. 77-52) are set forth in the following portions of
`
`these documents:
`
`1. Complaint (Doc. No. 1)
`
` ¶¶ 18-25, 43-113, 114-138, 140-497.
`
` Exs. D, E, U, V
`
`2. Memorandum of Points and Authorities in Support of Motion for
`
`Preliminary Injunction (Doc. No. 37-1)
`
` Pgs. 3-4, 7-12 (Doc. No. 37-1 at 8-9, 12-17)
`
`3. Declaration of Jim A. Youssef, M.D., in Support of NuVasive’s
`
`Motion for Preliminary Injunction (Doc. No. 37-45)
`
` ¶¶ 40-56, 58, 79-367
`
` Exs. V, W
`
` Appendices A-F
`
`4. Reply in Support of NuVasive’s Motion for Preliminary Injunction
`
`(Doc. No. 77)
`
` Pgs. 1-5, 8-9 (Doc. No. 77 at 7-11, 14-15)
`
`5. Reply Declaration of Jim A. Youssef, M.D. in Support of NuVasive’s
`
`Motion for Preliminary Injunction (Doc. No. 77-56)
`
` ¶¶ 41-42, 48, 50-51, 58-182, 393-394, and accompanying
`
`exhibits and citations
`
` Appendices G-L
`
`6. Reply Declaration of Matthew Link in Support of NuVasive’s Motion
`
`for Preliminary Injunction (Doc. No. 77-52)
`
` ¶¶ 57-68, and accompanying exhibits and citations
`
`
`
`
`
`
`
`NUVASIVE’S SUPPLEMENTAL
`RESPONSES TO 2nd SET OF
`INTERROGATORIES
`
`
`
`- 14 - 3:18-cv-00347-CAB-MDD
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`
`
`
`EXHIBIT 15 - Page 176
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-16 Filed 01/08/21 PageID.27104 Page 9 of
`17
`
`
`
`
`In addition, NuVasive states the following:
`
`XLIF
`
`The following components of XLIF, or their use, embody the asserted claims
`
`of the patents-in-suit:
`
`U.S. Patent No. 7,819,801:
`
`Claim
`
`Practicing Instrumentality
`
`1, 6, 15, 19,
`20, 23, 28, 29
`
`Dilators, Retractor (MaXcess I, MaXcess II, MaXcess III,
`MaXcess III Solid, MaXcess 4, and MaXcess 4 Solid), Shim
`
`2, 16
`
`26
`
`Dilators, Retractor (MaXcess I, MaXcess II, MaXcess III,
`MaXcess III Solid, MaXcess 4, and MaXcess 4 Solid), Shim,
`K-wire
`
`Dilators, Retractor (MaXcess I, MaXcess II, MaXcess III,
`MaXcess III Solid, MaXcess 4, and MaXcess 4 Solid), Shim,
`Shim Inserter
`
`U.S. Patent No. 8,355,780:
`
`Claim
`
`21, 22, 24, 26,
`28
`
`25
`
`27
`
`Practicing Instrumentality
`
`Dilators, Retractor (MaXcess I, MaXcess II, MaXcess III,
`MaXcess III Solid, MaXcess 4, and MaXcess 4 Solid)
`
`
`Dilators, Retractor (MaXcess I, MaXcess II, MaXcess III,
`MaXcess III Solid, MaXcess 4, and MaXcess 4 Solid), Shim
`
`Dilators, Retractor (MaXcess I, MaXcess II, MaXcess III,
`MaXcess III Solid, MaXcess 4, and MaXcess 4 Solid), K-
`wire
`
`U.S. Patent No. 8,439,832:
`
`Claim
`
`Practicing Instrumentality
`
`1, 2, 4, 6, 7,
`12, 13, 14, 17,
`19
`
`Dilators, Retractor (MaXcess I, MaXcess II, MaXcess III,
`MaXcess III Solid, MaXcess 4, and MaXcess 4 Solid), K-
`wire
`
`8, 16
`
`9
`
`Dilators, Retractor (MaXcess I, MaXcess II, MaXcess III,
`MaXcess III Solid, MaXcess 4, and MaXcess 4 Solid), Light
`Cable/light source connector
`
`Dilators, Retractor (MaXcess III, MaXcess III Solid,
`MaXcess 4, and MaXcess 4 Solid), Fourth Blade
`Attachment
`
`NUVASIVE’S SUPPLEMENTAL
`RESPONSES TO 2nd SET OF
`INTERROGATORIES
`
`
`
`- 15 - 3:18-cv-00347-CAB-MDD
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`
`
`
`EXHIBIT 15 - Page 177
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-16 Filed 01/08/21 PageID.27105 Page 10 of
`17
`
`
`
`
`U.S. Patent No. 9,833,227:
`
`Claim
`
`1, 2, 4, 6, 13,
`15, 16, 17, 19,
`22, 28
`
`Practicing Instrumentality
`
`Dilators, Retractor (MaXcess I, MaXcess II, MaXcess III,
`MaXcess III Solid, MaXcess 4, and MaXcess 4 Solid)
`
`U.S. Patent No. 8,753,270:
`
`Claim
`
`Practicing Instrumentality
`
`1, 2, 3, 4, 6, 12
`
`Intradiscal Shim
`
`U.S. Patent No. 8,361,156:
`
`Claim
`
`Practicing Instrumentality
`
`1, 2, 5, 9, 10,
`12, 13, 14, 15,
`16, 17, 18, 19,
`20, 24, 27
`
`CoRoent XL implants (e.g., CoRoent XL, CoRoent XLCT,
`CoRoent XLF, CoRoent XLK, CoRoent XLT, CoRoent
`XLW, CoRoent XL-FW, CoRoent XL-H, CoRoent XLXW,
`CoRoent XL+, CoRoent XL+ Wide)
`
`U.S. Patent No. 9,924,859:
`
`Claim
`
`1, 2, 3, 19, 20,
`21, 22, 23, 24,
`25, 26, 31, 32,
`33, 34, 35, 36
`
`4, 5, 6, 7, 8, 9,
`10, 11
`
`12, 13, 14, 15,
`16, 17, 18
`
`28, 29
`
`30
`
`Practicing Instrumentality
`
`Retractor (MaXcess 4), 4th Blade/Anterior Retractor, 4th
`Blade Attachment/Anterior Crossbar
`
`Retractor (MaXcess 4), 4th Blade/Anterior Retractor, 4th
`Blade Attachment/Anterior Crossbar, Access Driver
`Handles
`
`Dilators, Retractor (MaXcess 4), 4th Blade/Anterior
`Retractor, 4th Blade Attachment/Anterior Crossbar,
`Access Driver Handles
`
`Dilators, Retractor (MaXcess 4), 4th Blade/Anterior
`Retractor, 4th Blade Attachment/Anterior Crossbar
`
`K-Wire, Dilators, Retractor (MaXcess 4), 4th
`Blade/Anterior Retractor, 4th Blade Attachment/Anterior
`Crossbar
`
`U.S. Patent No. 9,974,531:
`
`Claim
`
`Practicing Instrumentality
`
`Dilators, Retractor (MaXcess I, MaXcess II, MaXcess III,
`1, 2, 3, 4, 8, 9,
`10, 11, 12, 13,
`MaXcess III Solid, MaXcess 4, and MaXcess 4 Solid), Access
`NUVASIVE’S SUPPLEMENTAL
`- 16 - 3:18-cv-00347-CAB-MDD
`RESPONSES TO 2nd SET OF
`INTERROGATORIES
`
`
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`
`
`
`EXHIBIT 15 - Page 178
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-16 Filed 01/08/21 PageID.27106 Page 11 of
`17
`
`
`
`
`14, 15, 16, 17,
`18, 19, 20, 21,
`22, 23, 24
`
`Driver Handles
`
`5, 6
`
`7
`
`25
`
`Dilators, Retractor (MaXcess I, MaXcess II, MaXcess III,
`MaXcess III Solid, MaXcess 4, and MaXcess 4 Solid), Access
`Driver Handles, Universal Clip
`
`K-Wire, Dilators, Retractor (MaXcess I, MaXcess II,
`MaXcess III, MaXcess III Solid, MaXcess 4, and MaXcess 4
`Solid), Access Driver Handles
`
`Dilators, Retractor (MaXcess I, MaXcess II, MaXcess III,
`MaXcess III Solid, MaXcess 4, and MaXcess 4 Solid), Access
`Driver Handles, Light Source/Connector
`
`26, 27, 28, 29,
`30, 31
`
`Dilators, Retractor (MaXcess I, MaXcess II, MaXcess III,
`MaXcess III Solid, MaXcess 4, and MaXcess 4 Solid), Access
`Driver Handles, Intradiscal Shim
`
`32, 33, 34, 35,
`36
`
`K-Wire, Dilators, Retractor (MaXcess I, MaXcess II,
`MaXcess III, MaXcess III Solid, MaXcess 4, and MaXcess 4
`Solid), Access Driver Handles, Intradiscal Shim
`
`37
`
`38
`
`39
`
`K-Wire, Dilators, Retractor (MaXcess I, MaXcess II,
`MaXcess III, MaXcess III Solid, MaXcess 4, and MaXcess 4
`Solid), Access Driver Handles, Light Source/Connector,
`Intradiscal Shim
`
`K-Wire, Dilators, Retractor (MaXcess I, MaXcess II,
`MaXcess III, MaXcess III Solid, MaXcess 4, and MaXcess 4
`Solid), Access Driver Handles, CoRoent XL (e.g., CoRoent
`XL, CoRoent XLCT, CoRoent XLF, CoRoent XLK, CoRoent
`XLT, CoRoent XLW, CoRoent XL-FW, CoRoent XL-H,
`CoRoent XLXW, CoRoent XL+, CoRoent XL+ Wide),
`Intradiscal Shim
`
`K-Wire, Dilators, Retractor (MaXcess I, MaXcess II,
`MaXcess III, MaXcess III Solid, MaXcess 4, and MaXcess 4
`Solid), Access Driver Handles, CoRoent XL (e.g.,CoRoent
`XL, CoRoent XLCT, CoRoent XLF, CoRoent XLK, CoRoent
`XLT, CoRoent XLW, CoRoent XL-FW, CoRoent XL-H,
`CoRoent XLXW, CoRoent XL+, CoRoent XL+ Wide)
`
`U.S. Patent No. 8,187,334:
`
`Claim
`
`6-9, 16, 18
`
`Practicing Instrumentality
`
`CoRoent XL implants (e.g., CoRoent XL, CoRoent XLCT,
`CoRoent XLF, CoRoent XLK, CoRoent XLT, CoRoent
`XLW, CoRoent XL-FW, CoRoent XL-H, CoRoent XLXW,
`CoRoent XL+, CoRoent XL+ Wide)
`
`NUVASIVE’S SUPPLEMENTAL
`RESPONSES TO 2nd SET OF
`INTERROGATORIES
`
`
`
`- 17 - 3:18-cv-00347-CAB-MDD
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`
`
`
`EXHIBIT 15 - Page 179
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-16 Filed 01/08/21 PageID.27107 Page 12 of
`17
`
`
`
`
`In addition, based on a reasonable investigation to date, including an
`
`investigation of information from the personal knowledge of those relevant persons
`
`still at or employed by NuVasive, NuVasive further states:
`
`NuVasive launched aspects of XLIF in October 2003 at the North American
`
`Spine Society (NASS) Annual Meeting, including its MaXcess access system, and
`
`specifically MaXcess I. Persons involved in this launch include Pat Miles, Eric
`
`Finley, and Scot Martinelli. In addition, MaXcess II Solid launched at NASS 2004,
`
`MaXcess II launched on August 29, 2005, MaXcess III launched on September 12,
`
`2006, MaXcess III Solid launched on November 13, 2008, and MaXcess 4
`
`launched on April 29, 2011. NuVasive further identifies Eric Finley as a current
`
`NuVasive employee that may have knowledge regarding the launch of the MaXcess
`
`I and II access systems.
`
`In October 2004, at NASS, NuVasive launched the CoRoent XL implant as a
`
`part of XLIF. The persons involved in the launch of CoRoent XL are Matthew
`
`Curran, Matthew Copp, Scot Martinelli, Patrick Miles, and David Ivanko. In
`
`addition, CoRoent XL-CT launched in 2008, CoRoent XL-F launched in 2008,
`
`CoRoent XL-W launched in 2008, and CoRoent XL-K launched in 2009.
`
`Additional current NuVasive employees who may have knowledge regarding the
`
`launches, uses, and sales of the various embodying CoRoent XL implants include
`
`Ryan Donahoe and Jeremy Malik.
`
`In addition, pursuant to Fed. R. Civ. P. 33(d), NuVasive has produced and
`
`will produce non-privileged documents from which the information regarding the
`
`launches, and disclosures, uses, and sales of NuVasive’s embodying products can
`
`be ascertained, including documents bearing the following Bates numbers:
`
`NUVA_ATEC0015491 – NUVA_ATEC0015614;
`
`NUVA_ATEC0040546 – NUVA_ATEC0040644;
`
`NUVA_ATEC0111926 – NUVA_ATEC0111927;
`
`NUVASIVE’S SUPPLEMENTAL
`RESPONSES TO 2nd SET OF
`INTERROGATORIES
`
`
`
`- 18 - 3:18-cv-00347-CAB-MDD
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`
`
`
`EXHIBIT 15 - Page 180
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-16 Filed 01/08/21 PageID.27108 Page 13 of
`17
`
`
`
`
`NUVA_ATEC0111974 – NUVA_ATEC0111985;
`
`NUVA_ATEC0111990 – NUVA_ATEC0111993;
`
`NUVA_ATEC0115139 – NUVA_ATEC0115153;
`
`NUVA_ATEC0119265 – NUVA_ATEC0119266.
`
`Finally, NuVasive’s Design History Files (“DHF”) for the various versions
`
`of the embodying components of XLIF (including the MaXcess access systems and
`
`CoRoent XL implants) contain NuVasive’s contemporaneous business records and
`
`documentation regarding, inter alia, the launch of such components, and include
`
`detailed information responsive to this interrogatory. The specific DHF documents
`
`produced as kept in NuVasive’s ordinary course of business and cited above are:
`
` DHF-01-002 (re dilators): NUVA_ATEC0000544 –
`
`NUVA_ATEC0009120, NUVA_ATEC0012840 –
`
`NUVA_ATEC0012926;
`
` DHF-02-006 (re access system): NUVA_ATEC0009121 –
`
`NUVA_ATEC0009814, NUVA_ATEC0012463 –
`
`NUVA_ATEC0012465, NUVA_ATEC0012618 –
`
`NUVA_ATEC0012620;
`
` DHF-03-003 (re implants): NUVA_ATEC0009815 –
`
`NUVA_ATEC0010067, NUVA_ATEC0012542 –
`
`NUVA_ATEC0012597;
`
` DHF-04-002 (re dilators); NUVA_ATEC0010068 –
`
`NUVA_ATEC0010509;
`
` DHF-04-004 (re light cables): NUVA_ATEC0010510 –
`
`NUVA_ATEC0011052, NUVA_ATEC0012430 –
`
`NUVA_ATEC0012462;
`
` DHF-06-008 (re shims and XLIF kit components):
`
`NUVA_ATEC0011053 – NUVA_ATEC0012429,
`
`NUVASIVE’S SUPPLEMENTAL
`RESPONSES TO 2nd SET OF
`INTERROGATORIES
`
`
`
`- 19 - 3:18-cv-00347-CAB-MDD
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`
`
`
`EXHIBIT 15 - Page 181
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-16 Filed 01/08/21 PageID.27109 Page 14 of
`17
`
`
`
`
`NUVA_ATEC0012466 – NUVA_ATEC0012541,
`
`NUVA_ATEC0012598 – NUVA_ATEC0012617,
`
`NUVA_ATEC0012621 – NUVA_ATEC0012839,
`
`NUVA_ATEC0012936 – NUVA_ATEC0012952;
`
` DHF-06-018 (re dilators): NUVA_ATEC0014000 –
`
`NUVA_ATEC0014446;
`
` DHF-08-012 (re shims and XLIF kit components):
`
`NUVA_ATEC13829 – NUVA_ATEC0013999;
`
` DHF-09-020 (re access system): NUVA_ATEC0012953 –
`
`NUVA_ATEC0013828;
`
` DHF-14-020 (re dilators): NUVA_ATEC0012927 –
`
`NUVA_ATEC0012935.
`
`The Accused Products
`
`NuVasive’s contentions and facts it intends to rely upon to support its
`
`contentions regarding the Accused Products within its June 29, 2018 Disclosure of
`
`Asserted Claims and Infringement Contentions are set forth in Sections I.b (pgs. 2-
`
`3), II.b. (pg. 7), III.b. (pgs. 11-12), IV.b. (pg. 16), V.b. (pg. 20), VI.b. (pg. 23),
`
`VII.b. (pg. 26-27), VIII.b. (pg. 30), IX.b. (pg. 34-35), and Exhibits A-I.
`
`Additionally, based on information available to NuVasive at this time,
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`NuVasive states that at least some of its employees received Alphatec’s October 18,
`
`21
`
`2016 press release announcing that Alphatec would feature a lateral spacer and
`
`22
`
`retractor system at NASS. In addition, at least some of NuVasive’s employees
`
`23
`
`were aware of Alphatec’s April 7, 2017 limited launch of the Accused Products.
`
`24
`
`On or around that same date, some NuVasive employees were also aware of
`
`25
`
`Alphatec’s website and surgical guide regarding Battalion Lateral. Finally,
`
`26
`
`Matthew Link provided a description of NuVasive’s awareness of the Accused
`
`27
`
`28
`
`
`
`NUVASIVE’S SUPPLEMENTAL
`RESPONSES TO 2nd SET OF
`INTERROGATORIES
`
`
`
`- 20 - 3:18-cv-00347-CAB-MDD
`
`EXHIBIT 15 - Page 182
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-16 Filed 01/08/21 PageID.27110 Page 15 of
`17
`
`
`
`
`Products in his Reply Declaration In Support of NuVasive’s Motion for Preliminary
`
`Injunction. See Doc. No. 77-52 at 3-6.
`
`Third Party Products
`
`NuVasive’s largest competitors with respect to MaXcess are Medtronic,
`
`DePuy/Synthes, Stryker Spine, Globus Medical, K2M, and Zimmer Biomet Spine.
`
`Additionally, based on a reasonable investigation to date, NuVasive has previously
`
`identified at least the following third party products as lateral competition:
`
`DLIF (Medtronic)
`
`Oracle (Synthes)
`
`Pipeline LS/Cougar (DePuy)
`
`MARS 3V/Transcontinental (Globus)
`
`Cross-Fuse (Pioneer)
`
`Ravine (K2M)
`
`GLIF (Alphatec)
`
`Finally, Matthew Link provided a description of how NuVasive has distinguished
`
`itself in the market from the third party products that Kelli Howell identified as
`
`competitors to XLIF. See Doc. No. 77-52 at 32-39.
`
`Discovery is ongoing and NuVasive reserves its right to amend or
`
`supplement its response to this interrogatory.
`
`INTERROGATORY NO. 14:
`
`Identify in detail the full factual and legal bases for the damages calculations
`
`that NuVasive alleges should be used in this case, including without limitation: (1)
`
`the amount of damages NuVasive claims under each damages theory and the
`
`specific inputs that NuVasive alleges should be used to calculate such damages; (2)
`
`if lost profits are sought, the basis for seeking such lost profits, and an identification
`
`of all facts, documents, and things supporting NuVasive’s determination of the
`
`alleged lost profits; (3) an identification of each sale NuVasive contends it lost as a
`
`NUVASIVE’S SUPPLEMENTAL
`RESPONSES TO 2nd SET OF
`INTERROGATORIES
`
`
`
`- 21 - 3:18-cv-00347-CAB-MDD
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`
`
`
`EXHIBIT 15 - Page 183
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-16 Filed 01/08/21 PageID.27111 Page 16 of
`17
`
`
`
`Dated: November 2, 2018 WILSON SONSINI GOODRICH & ROSATI, P.C.
`
`By: /s/ Christina Dashe
`
`Paul D. Tripodi II (SBN162380)
`ptripodi@wsgr.com
`Grace J. Pak (SBN 277705)
`gpak@wsgr.com
`633 West Fifth Street, Suite 1550
`Los Angeles, CA 90071
`Telephone: 323-210-2900
`Fax: 866-974-7329
`
`
`
`
`
`Natalie J. Morgan (SBN 211143)
`nmorgan@wsgr.com
`Christina Dashe (SBN 292360)
`cdashe@wsgr.com
`12235 El Camino Real
`San Diego, CA 92130
`Telephone: 858-350-2300
`Fax: 858-350-2399
`
`Wendy L. Devine (SBN 246337)
`wdevine@wsgr.com
`One Market Plaza,
`Spear Tower, Suite 3300
`San Francisco, CA 94105-1126
`Telephone: 415-947-2000
`Fax: 415-947-2099
`
`Sara L. Tolbert (SBN 300945)
`stolbert@wsgr.com
`650 Page Mill Road
`Palo Alto, CA 94304
`Telephone: 650-493-9300
`Fax: 650-493-6811
`
`
`
`
`
`
`
`
`
`
`NUVASIVE’S SUPPLEMENTAL
`RESPONSES TO 2nd SET OF
`INTERROGATORIES
`
`
`
`- 30 - 3:18-cv-00347-CAB-MDD
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`
`
`
`EXHIBIT 15 - Page 184
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-16 Filed 01/08/21 PageID.27112 Page 17 of
`17
`
`
`
`
`CERTIFICATE OF SERVICE
`
`
`The undersigned certifies that a true and correct copy of the foregoing
`
`document has been served on this date to all current and/or opposing counsel of
`
`record, if any to date, who are deemed to have consented to electronic service via
`
`the Court’s CM/ECF system per Civ.L.R. 5.4(d). Any other counsel of record will
`
`be served by electronic mail, facsimile and/or overnight delivery.
`
`I declare under penalty of perjury under the Laws of the United States of
`
`America that the above is true and correct. Executed this 2nd day of November,
`
`2018, at San Diego, California.
`
`
`
`By: /s/ Christina Dashe
`Christina Dashe
`
`CERTIFICATE OF SERVICE
`
`
`- 1 -
`
`
` 3:18-cv-00347-CAB-MDD
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`
`
`
`EXHIBIT 15 - Page 185
`
`